Nasus Pharma Ltd. has successfully completed a $15 million private placement to fund the clinical development of its lead product candidate, NS002, and to support additional product initiatives, attracting institutional investors and demonstrating confidence in its innovative intranasal drug delivery solutions.

Information on the target

Nasus Pharma Ltd. (NYSE: NSRX) is a clinical-stage pharmaceutical company based in Tel Aviv, Israel, specializing in the development of innovative intranasal products aimed at addressing acute medical conditions. The company is particularly focused on its lead product candidate, NS002, an intranasal powder formulation of Epinephrine designed as a needle-free alternative for the treatment of anaphylaxis. This product leverages Nasus Pharma's proprietary powder-based intranasal (PBI) technology, which facilitates rapid and reliable drug delivery through the nasal cavity's extensive vascular network.

With a commitment to advancing healthcare solutions, Nasus Pharma is dedicated to improving patient outcomes by providing easy-to-use, needle-free alternatives for emergency medical situations. The company is actively engaged in pivotal clinical trials and aims to expand its product pipeline to include additional intranasal therapies.

Industry overview in the target’s specific country

The pharmaceutical industry in Israel is recognized for its robust innovation and research capabilities, supported by a strong ecosystem of academic institutions, research centers, and venture capital. Israel has become a global hub for biotech and pharmaceutical development, with a signifi